Both of these players are leaders in their fields.

Zhengye receives a Nasdaq notice for failing to file its 2024 annual report on time. The company has 60 days to submit a compliance plan to avoid potential delisting. Get special access to three ...

These two biotechs only have one marketable therapy each, but both have blockbuster potential.

(RTTNews) - Several small- and mid-cap stocks posted notable gains in Wednesday's after-hours trading session, even though most companies did not release fresh news. The movement was largely driven by ...

(Bloomberg) -- The stock market’s recent wipeout has pushed a quarter of biotechnology stocks to trade below their cash holdings. That’s left bargain-hunters with a choice: Buy the dip or sit this one ...

TRINITY BIOTECH ($TRIB) is expected to release its quarterly earnings data on Thursday, May 22nd before market open, per Finnhub. Analysts are expecting revenue of ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.

Trinity Biotech plc (NASDAQ: TRIB) stock surged Tuesday after the diagnostics company announced a pair of developments that significantly altered its near- and long-term outlook. Investors reacted ...

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of ...

SAN DIEGO and CALGARY, AB, July 22, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a leading clinical-stage company specializing in ...

Oncolytics Biotech (NASDAQ:ONCY – Get Free Report)‘s stock had its “hold” rating reissued by research analysts at Jones Trading in a report released on Friday,Benzinga reports. Several other equities ...

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 ...